



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Trutakna

Page: 1 of 3

Effective Date: 9/30/2026

Last Review Date: 9/2026

Applies to:	☒ Illinois	☐ Florida	☒ Florida Kids
	☒ New Jersey	☒ Maryland	☐ Michigan
	☒ Pennsylvania Kids	☐ Virginia	☐ Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Trutakna under the patient's prescription drug benefit.

Description:

FDA-Approved Indications¹

Trutakna is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Trutakna

Policy/Guideline:

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- Initial requests:
 - Kidney biopsy confirming a diagnosis of primary immunoglobulin A nephropathy (IgAN).
 - Laboratory report and/or chart note(s) of baseline proteinuria or baseline urine protein-to-creatinine ratio (UPCR) obtained within 3 months prior to initiation of the requested drug.
- Continuation requests: Laboratory report and/or chart note(s) indicating the member has experienced benefit from therapy (e.g., decreased levels of proteinuria from baseline, decrease in UPCR from baseline, stabilization of proteinuria, UPCR, or kidney function).

Prescriber Specialties

This medication must be prescribed by or in consultation with a nephrologist.

	
AETNA BETTER HEALTH® Coverage Policy/Guideline	
Name: Trutakna	Page: 2 of 3
Effective Date: 9/30/2026	Last Review Date: 9/2026
Applies to: ☒ Illinois	☐ Florida
☒ New Jersey	☒ Maryland
☒ Pennsylvania Kids	☐ Virginia
	☒ Florida Kids
	☐ Michigan
	☐ Kentucky PRMD

Coverage Criteria

Primary Immunoglobulin A Nephropathy (IgAN)¹⁻⁵

Authorization of 12 months may be granted in adult members when all of the following criteria are met:

- Member has a diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy.
- Member has either of the following obtained within 3 months prior to initiation of the requested drug:
 - Proteinuria greater than or equal to 0.5 g/day
 - UPCR greater than or equal to 0.5 g/g
- Member has received a stable dose of maximally tolerated renin-angiotensin system (RAS) inhibitor therapy (e.g., angiotensin converting enzyme inhibitor [ACEI] or angiotensin II receptor blocker [ARB]) for at least 3 months prior to initiation of therapy, or member has an intolerance or contraindication to RAS inhibitors.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in all members (including new members) who are currently receiving the requested medication and who are experiencing benefit from therapy (e.g., decreased levels of proteinuria from baseline, decrease in UPCR from baseline, stabilization of proteinuria, UPCR, or kidney function).

Approval Duration and Quantity Restrictions:

Initial Approval: 12 months

Renewal Approval: 12 months

Quantity Level Limit: Trutakna 150 mg per mL prefilled single-dose autoinjector – 4 autoinjectors per 28 days

References:

1. Trutakna [package insert]. Brisbane, CA: Vera Therapeutics, Inc.; July 2026.
2. ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT04716231 Atacicept in subjects with IgA Nephropathy (ORIGIN 3): A Phase 3 Study with Atacicept in Subjects with IgA Nephropathy. September 30, 2025. Available from: <https://clinicaltrials.gov/study/NCT04716231>.
3. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025 Oct; 108 (4S): S1-S71.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Trutakna

Page: 3 of 3

Effective Date: 9/30/2026

Last Review Date: 9/2026

Applies to:	☒ Illinois	☐ Florida	☒ Florida Kids
	☒ New Jersey	☒ Maryland	☐ Michigan
	☒ Pennsylvania Kids	☐ Virginia	☐ Kentucky PRMD

4. Barrat J, Barbour SJ, Brenner RM et al. Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy. JASN. 2025; 36: 679-687.
5. Lafayette R, Barbour SJ, Brenner RM et al. A phase 3 trial of atacicept in patients with IgA nephropathy. The New England Journal of Medicine. 2026; 394 (7): 647-657.